Integrated BioPharma Inc (INBP) stock
INBPOTCPharmaceutical PreparationsFiscal year ends June 30
$0.18+0.00 (0.00%)
Close on Oct 19, 2026Market cap $5.59MP/E –Yield –
Integrated BioPharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Integrated BioPharma's revenue for the twelve months ending Jun 30, 2026 was $43.87M, down 19.3% year over year. For fiscal 2026 it was $43.87M, down 19.3% from the year before. Over ten years it grew 0.4% a year on average. The highest annual figure on record is $63.56M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $43.87M | -19.3% |
| FY2025 | Jun 30, 2025 | $54.35M | +8.0% |
| FY2024 | Jun 30, 2024 | $50.32M | -0.7% |
| FY2023 | Jun 30, 2023 | $50.67M | -9.9% |
| FY2022 | Jun 30, 2022 | $56.25M | -11.5% |
| FY2021 | Jun 30, 2021 | $63.56M | +20.4% |
| FY2020 | Jun 30, 2020 | $52.77M | +5.6% |
| FY2019 | Jun 30, 2019 | $49.98M | +14.3% |
| FY2018 | Jun 30, 2018 | $43.71M | -6.9% |
| FY2017 | Jun 30, 2017 | $46.95M | +11.2% |
| FY2016 | Jun 30, 2016 | $42.21M | +12.6% |
| FY2015 | Jun 30, 2015 | $37.49M | +11.3% |
| FY2014 | Jun 30, 2014 | $33.68M | +0.2% |
| FY2013 | Jun 30, 2013 | $33.62M | -8.1% |
| FY2012 | Jun 30, 2012 | $36.60M | -10.0% |
| FY2011 | Jun 30, 2011 | $40.67M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $9.80M | -30.9% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $10.11M | -27.5% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $11.28M | -10.6% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $12.69M | -6.8% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $14.18M | +11.2% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $13.95M | +6.1% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $12.61M | +9.6% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $13.62M | +5.4% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $12.75M | -1.9% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $13.15M | +0.4% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $11.51M | -6.1% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $12.92M | +4.8% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $12.99M | -2.1% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $13.10M | -16.2% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $12.25M | -16.0% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $12.33M | -3.3% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $13.27M | -22.2% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $15.63M | -8.4% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $14.59M | +2.4% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $12.75M | -16.0% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $17.06M | +26.0% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $17.07M | +25.2% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $14.26M | +0.4% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $15.17M | +33.0% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $13.54M | -0.4% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $13.63M | -3.2% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $14.20M | +18.3% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $11.41M | +10.7% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $13.58M | +8.1% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $14.09M | +33.2% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $12.00M | +11.1% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $10.30M | +5.5% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $12.57M | +11.7% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $10.58M | -0.7% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $10.80M | -12.7% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $9.77M | -23.0% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $11.25M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $10.65M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $12.37M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $12.68M | – |
See a number that looks wrong?